CanBas Co., Ltd.

2026/11/20 20:23 Updated
Market Cap: $98.2M (¥15.6B)
Stock Price: $4.98 (¥791)
Exchange Rate: 1 USD = ¥158.73

Stock Price Chart

2026/11/20 20:23 Updated
0.00
PER (Price Earnings Ratio)
vs Industry Avg: -9.6
12.81
PBR (Price to Book Ratio)
vs Industry Avg: +11.5
0.00%
Dividend Yield
vs Industry Avg: -2.95%

Price Trend

2026/11/20 20:23 Updated
Short-term
5-Day MA
+8.42%
Near-term
25-Day MA
+8.68%
Mid-term
75-Day MA
+4.44%
Long-term
200-Day MA
+7.97%

Price & Trading Details

2026/11/20 20:23 Updated

PRICE

Previous Close ¥774
Open ¥924
High ¥924
Low ¥787
Close ¥791

TRADING

Volume 3,731,900
Average Volume 177,296
Turnover ¥30億
Min. Purchase ¥79,100

Shareholder Composition

Updated 2026/11/01
7.2%
Insider Holdings
0.7%
Institutional
92.1%
Public Float
2
Institutional Holders
Insider Holdings 7.2%
Institutional 0.7%
Public Float 92.1%

Financial Performance

2026/11/22 Updated

No financial data available

Latest IR Information

Company Information

English Name CanBas Co., Ltd.
Japanese Name (株)キャンバス
Stock Code 4575.T (JPX)
Sector / Industry Healthcare / Biotechnology
Employees 18

About

CanBas Co., Ltd., a clinical stage biopharmaceutical company, engages in the basic research and clinical development of anti-cancer drugs. The company develops CBP501, a compound which regulates the regulatory function of the protein calmodulin in Phase 2 clinical trials targeting non-small cell lung cancer; and CBS9106 for patients with advanced solid tumors. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.

Data provided by Yahoo Finance